[go: up one dir, main page]

WO2005123121A3 - Use of dna molecule as vaccine adjuvant - Google Patents

Use of dna molecule as vaccine adjuvant Download PDF

Info

Publication number
WO2005123121A3
WO2005123121A3 PCT/GB2005/002472 GB2005002472W WO2005123121A3 WO 2005123121 A3 WO2005123121 A3 WO 2005123121A3 GB 2005002472 W GB2005002472 W GB 2005002472W WO 2005123121 A3 WO2005123121 A3 WO 2005123121A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna molecule
vaccine
antigen
fragment
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/002472
Other languages
French (fr)
Other versions
WO2005123121A2 (en
Inventor
Audun Helge Nerland
Niels Lorenzen
Ingunn Sommerset
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forinnova AS
Original Assignee
Forinnova AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0413973A external-priority patent/GB0413973D0/en
Priority claimed from GB0414091A external-priority patent/GB0414091D0/en
Application filed by Forinnova AS filed Critical Forinnova AS
Priority to CA 2572171 priority Critical patent/CA2572171A1/en
Priority to EP20050757731 priority patent/EP1784208A2/en
Publication of WO2005123121A2 publication Critical patent/WO2005123121A2/en
Publication of WO2005123121A3 publication Critical patent/WO2005123121A3/en
Anticipated expiration legal-status Critical
Priority to NO20070345A priority patent/NO20070345L/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/30011—Nodaviridae
    • C12N2770/30034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides the use of a DNA molecule encoding an antigen (and in particular encoding a bacteria or virus glycoprotein, preferably a rhabdovirus glycoprotein) which is expressed on the surface of a host cell, or variant, or a fragment thereof, in the manufacture of a medicament for use as a vaccine adjuvant or to enhance the immune stimulating properties or vaccination properties of a vaccine molecule, or to enhance the immune response to a vaccine molecule. A composition comprising said DNA molecule encoding an antigen which is expressed on the surface of a host cell, or variant, or a fragment thereof, and a vaccine molecule, is also provided. A further aspect of the present invention provides the use of said DNA molecule encoding an antigen which is expressed on the surface of a host cell, or variant, or a fragment thereof, in the manufacture of a composition which can improve or increase the elimination of other foreign DNA molecules from an organism.
PCT/GB2005/002472 2004-06-22 2005-06-22 Use of dna molecule as vaccine adjuvant Ceased WO2005123121A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA 2572171 CA2572171A1 (en) 2004-06-22 2005-06-22 Use of dna molecule as vaccine adjuvant
EP20050757731 EP1784208A2 (en) 2004-06-22 2005-06-22 Use of a dna molecule as vaccine adjuvant
NO20070345A NO20070345L (en) 2004-06-22 2007-01-18 Use of DNA molecule as a vaccine adjuvant

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0413973.9 2004-06-22
GB0413973A GB0413973D0 (en) 2004-06-22 2004-06-22 Use
GB0414091.9 2004-06-23
GB0414091A GB0414091D0 (en) 2004-06-23 2004-06-23 Use

Publications (2)

Publication Number Publication Date
WO2005123121A2 WO2005123121A2 (en) 2005-12-29
WO2005123121A3 true WO2005123121A3 (en) 2006-06-15

Family

ID=34981463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/002472 Ceased WO2005123121A2 (en) 2004-06-22 2005-06-22 Use of dna molecule as vaccine adjuvant

Country Status (4)

Country Link
EP (1) EP1784208A2 (en)
CA (1) CA2572171A1 (en)
NO (1) NO20070345L (en)
WO (1) WO2005123121A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100436599C (en) * 2006-05-12 2008-11-26 中国水产科学研究院黄海水产研究所 A PCR method for female-specific AFLP fragments and genetic sex identification in half-smooth tongue sole
CN101914529B (en) * 2010-07-29 2012-03-14 中国水产科学研究院黄海水产研究所 Cynoglossus semilaevis gunther sex-linked microsatellite marker and genetics sex testing method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOUDINOT P ET AL: "Combined DNA Immunization with the Glycoprotein Gene of Viral Hemorrhagic Septicemia Virus and Infectious Hematopoietic Necrosis Virus Induces Double-Specific Protective Immunity and Nonspecific Response in Rainbow Trout", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 249, no. 2, 30 September 1998 (1998-09-30), pages 297 - 306, XP004445647, ISSN: 0042-6822 *
NIELS LORENZEN ET AL.: "Immunity induced shortly after DNA vaccination of rainbow trout against rhabdoviruses protects against heterologous virus but not against bacterial pathogens", DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, vol. 26, 2002, pages 173 - 179, XP002347949 *
SOMMERSET I ET AL: "A DNA vaccine directed against a rainbow trout rhabdovirus induces early protection against a nodavirus challenge in turbot", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 32, 1 December 2003 (2003-12-01), pages 4661 - 4667, XP004469682, ISSN: 0264-410X *

Also Published As

Publication number Publication date
CA2572171A1 (en) 2005-12-29
WO2005123121A2 (en) 2005-12-29
NO20070345L (en) 2007-03-02
EP1784208A2 (en) 2007-05-16

Similar Documents

Publication Publication Date Title
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
EP2762165A3 (en) Composition comprising a complexed (m)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010138263A3 (en) Novel aav 's and uses thereof
SI1951296T2 (en) Cell-derived viral vaccines with low levels of residual cell dna by betapropiolactone
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
EA200700849A1 (en) PRIMARY / BOOSTER ANTI-MALARY VACCINE
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2008079372A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2008083239A3 (en) Compositions and methods for stimulating an immune response
WO2006045796A3 (en) Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
WO2008133208A1 (en) Method for enhancing immune response with peptide
WO2008017826A3 (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
BRPI0816134A2 (en) Herpesvirus, DNA sequence, vector, cell, virus, method for producing infectious particles, infectious particles, vaccine, use of herpesvirus or DNA sequence or vector or infectious particles, and method for preventive and / or treatment. treatment of a disease.
MXPA02001223A (en) Proteins derived from white spot syndrome virus and uses thereof.
MXPA05005203A (en) Vaccine against hcv.
WO2008082719A3 (en) Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
WO2003095480A3 (en) Brachyspira hyodysenteriae vaccine
WO2005123121A3 (en) Use of dna molecule as vaccine adjuvant
WO2008027560A3 (en) Holin-enhanced vaccines and reagents, and methods of use thereof
TW200637573A (en) Peptide for delivery of mucosal vaccines
WO2004007726A3 (en) Brachyspira hyodysenteriae vaccine
NO20081541L (en) New sea lice vaccine
WO2006109071A3 (en) Vaccine against burkholderia infections
EP1090995A3 (en) Mycoplasma hyopneumoniae antigen MHP3, gene encoding it and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2572171

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005757731

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 599/DELNP/2007

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2005757731

Country of ref document: EP